If you have not heard that glial cells are involved in pain processing then you have missed some significant advances in our understanding of the generation and maintenance of pain [3] . It is well established that spinal astrocytes and microglial cells become activated after peripheral nerve injury. The stream of incoming primary afferent activity that accompanies such injury bombards the spinal cord with a variety of neurotransmitters, including substance P (Sub-P) (Fig. 1) . Microglial cells exposed to Sub-P increase their expression of OX-42 as well as their expression of inflammatory mediators, such as tumor necrosis factor alpha (TNF-alpha) and chemokine ligand 2 (CCL2) [1, 4] . That this process is involved in the generation of pain is borne out by the finding that preventing or reversing the activation of microglial cells with minocycline reduces nerve injury-associated pain behavior [5] . Consistent with these observations, intrathecal administration of the TNF-alpha inhibitor, etanercept, is antinociceptive.
Despite the effects of inhibiting TNF-alpha, surprisingly intrathecal administration of TNF-alpha, itself, has no effect on nociceptive thresholds [8] . What could account for these somewhat paradoxical effects on nociceptive processing? In this issue of PAIN, Zhou and colleagues enlighten us with a new explanation as to how TNF-alpha produced by activated microglia contributes to the development of neuropathic pain. The take home message is that the TNF-alpha that plays a role in nociception is not released. Rather, it is membrane bound.
Prior to explaining how the authors came to this conclusion, a little background is in required. TNF-alpha is first produced as a long, membrane bound molecule, called mTNF-alpha (Fig. 1) . To be released into the extracellular environment, mTNF-alpha is cleaved to the soluble form of TNF-alpha (sTNF-alpha) by the TNF-alpha converting enzyme (TACE). TACE is an inducible enzyme, which means that unless it is turned on, mTNF-alpha remains intact and there is no release of sTNF-alpha. Step 1: substance P (Sub-P) is released by primary afferents and activates Sub-P receptors (NK1-R) on microglial cells.
Step 2: Sub-P stimulated microglial cells increase their expression of membrane bound tumor necrosis factor (mTNF-alpha). Because NK1-R stimulation does not activate the TNF-alpha converting enzyme (TACE), mTNF-alpha is not converted to the soluble form of TNF-alpha (sTNF-alpha).
Step 3: the activation of neighboring, unstimulated, microglial cells occurs through direct contact between mTNF-alpha and TNF-alpha receptors (TNF-alphaR).
Step 4: TNF-alphaR stimulation induces an increase of OX-42 levels and evokes the release of chemokine ligand 2(CCL2). The latter, in turn, activates spinal neurons, which induces and maintains neuropathic pain.
